West Coast Sarcoma Conference 2024: Session 3 – Rhabdomyosarcoma – Is the Pathway the Same For All?
OR
Chair
Dr. Lee Cranmer
Speakers
Dr. Jinesa Moodley
Dr. Bilal Marwa
Dr. Karen Goddard
Dr. Jeremy Sharib
Studies/trials discussed:
- A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-Related Fusions in Infantile Cases
- Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children’s Oncology Group
- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children’s Oncology Group
- ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.
- Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma
- Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases
